The F13A1 gene provides instructions for part of factor XIII, a protein that strengthens blood clots after bleeding starts. This gene helps your body seal injuries more firmly, so if it does not work well, clots may form but break apart too soon. People with pathogenic variants in the F13A1 gene can have easy bruising, nosebleeds, longer bleeding after injury or surgery, slow wound healing, and repeated pregnancy loss. In some people, bleeding can also happen inside the body, including the brain.
What is a gene?
Genes are stretches of DNA that give your cells instructions they can use to make molecules or direct processes in the body. Some genes provide the code for proteins, the parts of cells that do the work. Others mainly regulate when certain processes happen, where they happen, and how strongly they run. In combination, genes influence how the body develops and functions, and they can also shape how you respond to food, stress, or medications. For a deeper look at this topic, you can read more in the LearnHub.
Overview
F13A1Gene function
What if the gene works
The F13A1 gene helps make factor XIII A, a blood clotting protein. It strengthens new clots by linking fibrin strands together, which helps control bleeding and supports wound healing.
Risk
What if the gene does not work
Variants in the F13A1 gene can cause factor XIII deficiency, which may lead to easy bruising, poor wound healing, deep bleeding, bleeding inside the skull, or repeated pregnancy loss. More severe variants often cause earlier and broader symptoms.
Treatment
What does that mean for your treatment
Pathogenic variants in the F13A1 gene can make factor XIII replacement the key treatment, often on a regular schedule to lower bleeding risk. Recombinant factor XIII is used specifically for F13A1-related A subunit deficiency, while plasma-derived factor XIII products are another established option. Extra replacement may be needed before surgery, dental work, or after a bleed.
Conditions associated with F13A1
Gene function
What if the gene works
When you cut yourself, your body first makes a soft blood clot. The F13A1 gene gives instructions for a key part of factor XIII, a protein that strengthens that clot so it can hold together. This supports early healing and helps the body seal injured tissue more securely.
The F13A1 gene helps turn a soft early clot into a firmer one. Its protein links fibrin strands together, a key step in how the F13A1 gene helps blood clotting after an injury.
This protein also helps attach a natural clot protecting partner called alpha2-antiplasmin to the fibrin mesh. That makes the clot less likely to be cleared away before the injured area has sealed.
Factor XIII A also supports the scaffold around a wound by linking some tissue proteins into place. This helps the fresh clot stay attached while the body begins repair.
What is a variant?
A genetic variant is a small difference in the DNA sequence within a gene. These differences are common and help make up normal human diversity, including differences in appearance, metabolism, or how the body responds to environmental influences. Many variants do not cause any noticeable effect and are simply part of natural genetic variation. In some situations, though, a variant changes how a gene works more substantially and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Variants in the F13A1 gene can lower the amount of factor XIII A made, make the protein unstable, or weaken the chemical step that links clot proteins together. This is how variants in the F13A1 gene affect clot stability at a cellular level. When both gene copies are affected, more severe loss of function variants may leave little or no activity, while milder variants can preserve some activity, often influencing how early bleeding symptoms appear and how pronounced they are.
How variants are linked to conditions
Pathogenic variants in the F13A1 gene cause congenital factor XIII A subunit deficiency, a rare inherited bleeding condition. People with this diagnosis may have delayed bleeding after injury or surgery, easy bruising, nosebleeds, poor wound healing, or recurrent pregnancy loss. In severe cases, bleeding inside the skull can occur, sometimes early in life. Information about the F13A1 gene and factor XIII deficiency is most relevant when a pathogenic variant is found on both copies of the gene.
A variant is not necessarily a diagnosis
Genetic variants are a normal feature of human biology and are common throughout the general population. Most do not have a direct effect on health and simply reflect natural human diversity. For many genes, carrying a variant associated with a condition suggests a possible link rather than a definite diagnosis, especially when more than one gene and environmental factors are involved. In some situations, though, a single well-characterized variant in a particular gene can be enough to confirm a diagnosis.
Are there things that can increase or change my risk?
For F13A1, risk is mainly shaped by inherited gene changes rather than lifestyle. A child is more likely to have factor XIII deficiency if both parents carry a harmful F13A1 change, so family history and parents being blood relatives can raise the chance. There is not enough evidence to say diet, exercise, or everyday habits lower this inherited risk.
Inheritance of F13A1 variants
F13A1-related inherited factor XIII deficiency follows an autosomal recessive pattern. In practical terms, inheritance of F13A1 gene variants usually means a child must receive one altered copy from each parent to have the condition. When both parents are carriers, each pregnancy has a 25% chance of an affected child, a 50% chance of a carrier child, and a 25% chance of a child with two working copies. This pattern applies equally to sons and daughters.
What does my F13A1 result mean for my family?
For families with an F13A1-related condition, the pattern is usually recessive, which means parents often carry the gene change without having symptoms themselves. Brothers and sisters of an affected child may also be affected or may be healthy carriers, so relatives may want to learn whether the same change runs in the family. Children of someone with an F13A1-related condition will usually be carriers unless the other parent also carries an F13A1 change.
Genetic information
Genetic testing
How you find out about variants
To find variants in the F13A1 gene, doctors use genetic testing for F13A1 variants on a blood or saliva sample. A lab reads the gene's DNA code to look for changes that may help confirm inherited factor XIII deficiency or show whether someone carries a familial variant.
When should I consider getting a genetic test?
Consider testing the F13A1 gene if there is a family history of factor XIII deficiency or unusual bleeding, especially bleeding from the umbilical cord at birth, repeated nosebleeds, deep bruising, or delayed bleeding after surgery. Testing can also help explain repeated pregnancy loss in some families.
A genetic result is only one part of your health story
Genetic results can be informative, but how much they explain varies with the condition and the kind of variant found. Over time, the body is shaped by many factors, including lifestyle, environment, age, and medical history. For some conditions, particularly those affected by many genes, genetic information provides context rather than certainty and makes the most sense when considered with the rest of a person’s care. In other situations, a genetic result can give a more definite answer. For medication response as well, genetic results can help put a person’s experience into context.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. Small differences in DNA can change how the body processes a drug or how strongly the drug acts on its target, so the same treatment may work differently from one person to another. This kind of variation is common and can influence how much benefit a medicine gives or how sensitive someone is to side effects.
What is Pharmacogenetics?
Pharmacogenetics looks at how genetic differences can shape a person’s response to medications. It examines links between genes and drugs to help explain why the same treatment can work differently from one person to another. With many medications, genes can affect both how strong a drug’s effects are and how the body processes it. This understanding can support treatment choices that are more informed and more individualized. More detail on this topic is available in the LearnHub.
Drugs influenced by the F13A1 gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in guiding medication response, so concerns about bleeding, easy bruising, clotting, or side effects from any medicine are best discussed with your doctor.
History
Factor XIII first drew medical attention in the mid 1900s, when researchers realized that some people formed blood clots that looked normal at first but later broke down too easily. In 1960, Swiss physician Franz Duckert described an inherited factor XIII deficiency, a landmark report that helped doctors recognize this as a distinct bleeding condition. Early reports called it “Duckert syndrome,” though that term has since evolved. From these first observations, research expanded steadily. By the 1980s, scientists had identified and mapped the F13A1 gene, linking changes in this gene to the A subunit of factor XIII. That work helped bring rare bleeding conditions into the growing field of molecular genetics.